High-Dose Aumolertinib Shows Durable CNS Response in EGFR-Mutant NSCLC With Brain Metastases
The ACHIEVE phase 2 trial (n=63) demonstrated that high-dose aumolertinib achieved 88.9% systemic and 82.5% intracranial response rates in untreated EGFR-mutant NSCLC with brain metastases, with median PFS of 20.5 months. Notably, EGFR variant clearance in plasma ctDNA at cycle 2 independently predicted longer PFS (HR 0.14), supporting ctDNA as an early response biomarker for CNS-directed therapy.
The original study
High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.
- Authors
- Li H, Chen K, Gong L, Qin J, Jin Y, Zhou R, et al.
- Journal
- JAMA oncology
- Type
- Clinical Trial, Phase II, Journal Article, Multicenter Study
- PMID
- 40569623
Original abstract
IMPORTANCE: Central nervous system (CNS) metastases remain a significant challenge in the management of EGFR-variant non-small cell lung cancer (NSCLC). OBJECTIVE: To evaluate the activity and safety of high-dose aumolertinib in patients with untreated EGFR-variant NSCLC and brain metastases. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2 nonrandomized clinical trial conducted at 10 centers in China. Patients with untreated EGFR-variant metastatic NSCLC and brain metastases were enrolled between July 6, 2021, and August 31, 2022. The data cutoff date was October 10, 2024. INTERVENTIONS: Patients received aumolertinib, 165 mg, orally once daily until disease progression or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: The primary end point was 12-month progression-free survival (PFS) rate assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1. RESULTS: A total of 63 patients (39 female [61.9%]; median age, 60 [range, 47-76] years) were enrolled (full analysis set), and 49 had at least 1 measurable brain lesion (CNS evaluable-for-response set). Median follow-up duration was 28.8 months (95% CI, 27.0-29.8). In the full analysis set, the 12-month PFS rate was 62.1% (95% CI, 48.7-73.0), the median PFS was 20.5 months (95% CI, 12.0-26.9), the 12-month intracranial PFS rate was 76.8% (95% CI, 63.2-85.9), and the median intracranial PFS and overall survival were not reached. Systemic and intracranial objective response rates per RECIST 1.1 were 56 of 63 (88.9% [95% CI, 78.4-95.4]) and 52 of 63 (82.5% [95% CI, 70.9-90.9]) in the full analysis set and 43 of 49 (87.8% [95% CI, 75.2-95.4]) and 42 of 49 (85.7% [95% CI, 72.8-94.1]) in the CNS evaluable-for-response set, respectively. The most common grade 3 or 4 treatment-related adverse event was increased blood creatine phosphokinase (17 participants [27.0%]). No treatment-related deaths occurred. EGFR variant clearance in plasma circulating tumor DNA at day 1 of cycle 2 was independently associated with longer PFS (hazard ratio, 0.14 [95% CI, 0.04-0.47]; P = .001). CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest that high-dose aumolertinib is associated with long-term survival benefit in patients with untreated EGFR-variant NSCLC and brain metastases, with a manageable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04808752.